Opportunity Information: Apply for PAR 28 062
Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional) is an NIH funding opportunity from the National Cancer Institute that uses a cooperative agreement mechanism (U54) to support structured, multi-component partnerships focused on improving cancer research capacity and impact. The competition is described as limited, meaning only organizations that meet the specific eligibility requirements in Section III of the NOFO should apply. Applications will go through standard NIH peer review, and only proposals judged to be highly meritorious will be considered for funding.
At its core, CAPRI is designed to build and strengthen long-term, genuinely collaborative relationships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs). The program emphasis is not just on running isolated projects, but on creating comprehensive, mutually beneficial partnerships that can accelerate collaborative and innovative cancer research. In practical terms, CAPRI aims to help RLIs expand the institutional foundation needed to compete and contribute in cancer research, while also enabling cancer centers to broaden the reach, relevance, and inclusivity of their research through strong, sustained engagement with partner institutions and the communities they serve.
The program’s goals span both infrastructure and people. On the institutional side, CAPRI seeks to strategically build capacity and strengthen research infrastructure at participating institutions, enhancing their ability to plan, execute, and sustain high-quality cancer research programs. On the research side, the opportunity supports advancing research capabilities and increasing the impact of innovative cancer research produced through these partnerships. On the workforce development side, CAPRI places clear value on cultivating the next generation of cancer researchers by supporting Early-Stage Investigators and trainees, positioning training and career development as a central piece of the partnership rather than an add-on. In addition, CAPRI includes a strong expectation for coordinated outreach and education activities so that the benefits of research are not confined to academic settings but extend to populations nationwide, supporting broader dissemination, engagement, and potential improvements in cancer-related outcomes.
The award is labeled “Clinical Trial Optional,” which signals that applicants may propose clinical trial activities if they fit the partnership’s objectives, but proposing a clinical trial is not required to be responsive. Because the funding instrument is a cooperative agreement, recipients should also expect a more involved partnership with NIH/NCI compared with a standard grant, typically including substantial federal programmatic involvement in coordination, oversight, or collaborative steering consistent with the U54 mechanism.
Eligibility is broad across U.S.-based organizational types, but foreign involvement is explicitly restricted. Eligible applicants listed include independent school districts, public and state-controlled institutions of higher education, and nonprofit organizations (both with and without 501(c)(3) status, as specified), along with other eligible entities identified in the NOFO. Additional eligible applicant categories noted include eligible federal agencies, U.S. territories or possessions, faith-based or community-based organizations, and regional organizations, with the reminder that applicants should consult Section III for the full and controlling eligibility requirements. Importantly, non-U.S. entities are not eligible to apply, non-U.S. components of U.S. organizations are not eligible to apply, and foreign components (as defined in the NIH Grants Policy Statement) are not allowed under this opportunity.
Administratively, this opportunity is listed under Funding Opportunity Number PAR-28-062, falls under the health funding activity category, and is associated with CFDA 93.399. The original closing date provided is January 25, 2027. The notice does not specify an award ceiling or number of expected awards in the provided excerpt, so applicants would need to consult the full NOFO for any budget limits, project period details, required components, partnership structure expectations, and review criteria that would determine how proposals should be organized and what reviewers will weigh most heavily.Apply for PAR 28 062
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.399.
- This funding opportunity was created on 2026-08-31.
- Applicants must submit their applications by 2027-01-25.
- Eligible applicants include: Independent school districts, Public and State controlled institutions of higher education, Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)
What is the CAPRI funding opportunity?
CAPRI (Cancer Advancement through Partnerships in Research and Infrastructure) is an NIH funding opportunity from the National Cancer Institute (NCI) that uses a cooperative agreement mechanism (U54) to support structured, multi-component partnerships intended to improve cancer research capacity and impact.
Which NIH/NCI mechanism does CAPRI use?
CAPRI uses the U54 cooperative agreement mechanism. This generally indicates a more substantial level of NIH/NCI programmatic involvement than a standard grant, including coordination, oversight, or collaborative steering consistent with the U54 model.
What does "cooperative agreement" mean for applicants and awardees?
Because CAPRI is a cooperative agreement (U54), awardees should expect an involved partnership with NIH/NCI compared with typical grant mechanisms. The federal role may include significant programmatic involvement in coordination, oversight, and other collaborative activities aligned with the program goals.
What does "Clinical Trial Optional" mean?
"Clinical Trial Optional" means applicants may propose clinical trial activities if they align with the partnership's objectives, but proposing a clinical trial is not required to be responsive to the opportunity.
Is this a limited competition?
Yes. The competition is described as limited, meaning only organizations that meet the specific eligibility requirements in Section III of the Notice of Funding Opportunity (NOFO) should apply.
Who is CAPRI designed to support?
CAPRI is designed to build and strengthen long-term, genuinely collaborative relationships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs).
What is the core purpose of CAPRI partnerships?
The program emphasizes comprehensive, mutually beneficial partnerships rather than isolated projects. The intent is to accelerate collaborative and innovative cancer research while strengthening research capacity at RLIs and expanding reach, relevance, and inclusivity for cancer centers through sustained engagement with partner institutions and the communities they serve.
What are the main goals of CAPRI?
CAPRI goals span infrastructure, research, and workforce development. The program aims to (1) strategically build capacity and strengthen research infrastructure at participating institutions, (2) advance research capabilities and increase the impact of innovative cancer research produced through partnerships, and (3) cultivate the next generation of cancer researchers by supporting Early-Stage Investigators and trainees as a central part of the partnership.
How does CAPRI address research infrastructure and institutional capacity?
CAPRI seeks to strengthen the institutional foundation needed to plan, execute, and sustain high-quality cancer research programs, particularly at participating Resource Limited Institutions (RLIs), as part of a broader, long-term partnership model.
Does CAPRI include training and career development expectations?
Yes. CAPRI places clear value on workforce development, including support for Early-Stage Investigators and trainees. Training and career development are positioned as a central component of the partnership rather than an add-on.
Are outreach and education activities expected under CAPRI?
Yes. CAPRI includes a strong expectation for coordinated outreach and education activities so that the benefits of research extend beyond academic settings to populations nationwide, supporting broader dissemination, engagement, and potential improvements in cancer-related outcomes.
How will CAPRI applications be reviewed?
Applications will go through standard NIH peer review. Only proposals judged to be highly meritorious will be considered for funding.
Who is eligible to apply?
Eligibility is broad across U.S.-based organizational types, but applicants must meet the specific and controlling eligibility requirements in Section III of the NOFO. Eligible applicants listed include independent school districts, public and state-controlled institutions of higher education, and nonprofit organizations (with and without 501(c)(3) status, as specified). Additional categories noted include eligible federal agencies, U.S. territories or possessions, faith-based or community-based organizations, and regional organizations.
Are foreign organizations eligible to apply?
No. Non-U.S. entities are not eligible to apply.
Can a U.S. organization apply if it has a non-U.S. component?
No. Non-U.S. components of U.S. organizations are not eligible to apply under this opportunity.
Are foreign components allowed in the project?
No. Foreign components (as defined in the NIH Grants Policy Statement) are not allowed under this opportunity.
What is the Funding Opportunity Number for CAPRI?
The Funding Opportunity Number is PAR-28-062.
What is the associated CFDA number?
The opportunity is associated with CFDA 93.399.
What is the funding activity category?
The opportunity falls under the health funding activity category.
What is the application closing date listed in the excerpt?
The original closing date provided is January 25, 2027.
Does the excerpt specify an award ceiling or number of expected awards?
No. The provided excerpt does not specify an award ceiling or the number of expected awards. Applicants would need to consult the full NOFO for budget limits, expected number of awards (if listed), and related fiscal details.
Where should applicants look for the full eligibility rules and required components?
Applicants should consult Section III of the NOFO for the full and controlling eligibility requirements. The excerpt also notes that applicants should consult the full NOFO for budget limits, project period details, required components, partnership structure expectations, and review criteria.
Is CAPRI focused on short-term projects or long-term collaboration?
CAPRI emphasizes long-term, genuinely collaborative relationships between partner institutions, with structured, multi-component partnerships designed to strengthen research capacity and increase research impact over time.
How does CAPRI aim to improve inclusivity and relevance in cancer research?
By supporting strong, sustained engagement between RLIs and NCI-designated Cancer Centers, CAPRI aims to broaden the reach, relevance, and inclusivity of cancer research, including through coordinated outreach and education activities that extend benefits to populations nationwide.
Browse more opportunities from the same category: Health
Previous opportunity: Alumni Engagement Innovation Fund 2026
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 28 062
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 28 062) also looked into and applied for these:
| Funding Opportunity |
|---|
| NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required) Apply for PAR 27 065 Funding Number: PAR 27 065 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required) Apply for RFA DK 27 139 Funding Number: RFA DK 27 139 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed) Apply for PAR 27 051 Funding Number: PAR 27 051 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional) Apply for PAR 27 127 Funding Number: PAR 27 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required) Apply for RFA CA 27 005 Funding Number: RFA CA 27 005 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| Limited Competition: Centers of Biomedical Research Excellence: Development Phase (COBRE-D) (P30 - Clinical Trial Not Allowed) Apply for PAR 27 054 Funding Number: PAR 27 054 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required) Apply for RFA DK 27 125 Funding Number: RFA DK 27 125 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cooperative Centers for Experimental Hematology (CCEHs) (U54- Clinical Trial Not Allowed) Apply for RFA DK 27 127 Funding Number: RFA DK 27 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) Apply for RFA AI 27 002 Funding Number: RFA AI 27 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional) Apply for PAR 27 056 Funding Number: PAR 27 056 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Not Allowed) Apply for PAR 27 112 Funding Number: PAR 27 112 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: NIGMS Mature Synchrotron Resources (MSR) for Structural Biology (P30 - Clinical Trial Not Allowed) Apply for PAR 27 068 Funding Number: PAR 27 068 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Long-term health outcomes of people living with spina bifida Apply for CDC RFA DD 26 0222 Funding Number: CDC RFA DD 26 0222 Agency: Centers for Disease Control - NCBDDD Category: Health Funding Amount: $300,000 |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) Apply for RFA AI 27 005 Funding Number: RFA AI 27 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Lasker Clinical Research Scholar's Program (Si2/R00 Clinical Trial Optional) Apply for PAR 27 076 Funding Number: PAR 27 076 Agency: National Institutes of Health Category: Health Funding Amount: $499,000 |
| Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed) Apply for RFA DK 27 112 Funding Number: RFA DK 27 112 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) Apply for PAR 27 053 Funding Number: PAR 27 053 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed) Apply for RFA AI 27 014 Funding Number: RFA AI 27 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Trauma Care Readiness and Coordination Cooperative Agreement Apply for EP U3R 26 002 Funding Number: EP U3R 26 002 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $500,000 |
| Improving the Capacity of Tribal Communities to Identify Emerging Drug Threats Apply for RD ET RDA 26 002 Funding Number: RD ET RDA 26 002 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 28 062", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.